National Research Corp files Form 4 for 22,625 director options
Rhea-AI Filing Summary
National Research Corp (NRC) reported a director equity award on Form 4. On 10/17/2025, the reporting person received a Director Stock Option grant for 22,625 options at an exercise price of $11.61 per share. The award vests/becomes exercisable on 10/17/2025 and expires on 10/17/2035, with 22,625 derivative securities beneficially owned directly after the grant. The filing notes the grant was made under the Issuer’s 2025 Omnibus Incentive Plan for participating in two in-person meetings during 2025.
Positive
- None.
Negative
- None.
Insights
Routine director stock option grant; neutral impact.
NRC disclosed a director stock option award of 22,625 options at an exercise price of $11.61. The option is listed as exercisable on 10/17/2025 and expires on 10/17/2035, recorded as directly owned following the grant.
The filing states the award was granted under the 2025 Omnibus Incentive Plan for participation in two in-person meetings during 2025. Such grants are a standard component of non-employee director compensation and do not, by themselves, alter the company’s operating outlook.
Actual dilution depends on future exercises, which require paying the $11.61 exercise price. Subsequent disclosures may detail additional director awards or plan activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 22,625 | $0.00 | -- |
Footnotes (1)
- [object Object]
FAQ
What did NRC disclose on this Form 4?
When do the NRC director options vest and expire?
What plan covers the NRC director’s option grant?
How many derivative securities does the director hold after the grant?
What was the stated reason for the option grant at NRC?
What is the exercise price of the NRC director stock options?